thalidomide has been researched along with Hypersensitivity in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hypersensitivity: Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although thalidomide-induced dermatologic disorders rarely were reported before thalidomide was administered to patients positive for the human immunodeficiency virus, hypersensitivity reactions including rash are the agent's major dose-limiting toxicities in this population." | 3.70 | Thalidomide-induced toxic epidermal necrolysis. ( Horowitz, SB; Stirling, AL, 1999) |
| "Thalidomide, which was initially used as an anti-emetic drug but was withdrawn due to its teratogenic effects, is now used to treat blood cancers." | 1.91 | Thalidomide Attenuates Mast Cell Activation by Upregulating SHP-1 Signaling and Interfering with the Action of CRBN. ( Chang, HW; Lee, YJ; Sim, KH, 2023) |
| " Prednisolone in standard dosage schedule as recommended by WHO is now being widely used in control programmes." | 1.32 | Reactions and their management. ( Ganapati, R; Pai, VV, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, HW | 1 |
| Sim, KH | 1 |
| Lee, YJ | 1 |
| Leon, KE | 1 |
| Salinas, JL | 1 |
| McDonald, RW | 1 |
| Sheth, AN | 1 |
| Fairley, JK | 1 |
| Ganapati, R | 1 |
| Pai, VV | 1 |
| Horowitz, SB | 1 |
| Stirling, AL | 1 |
4 other studies available for thalidomide and Hypersensitivity
| Article | Year |
|---|---|
Thalidomide Attenuates Mast Cell Activation by Upregulating SHP-1 Signaling and Interfering with the Action of CRBN.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Hypersensitivity; Mast | 2023 |
Complex Type 2 Reactions in Three Patients with Hansen's Disease from a Southern United States Clinic.
Topics: Adult; Aged; Anti-Inflammatory Agents; Asia, Southeastern; Bangladesh; Erythema Nodosum; Female; Geo | 2015 |
Reactions and their management.
Topics: Arthritis; Cicatrix; Clofazimine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Ad | 2004 |
Thalidomide-induced toxic epidermal necrolysis.
Topics: Angiogenesis Inhibitors; Female; Glioblastoma; Humans; Hypersensitivity; Middle Aged; Stevens-Johnso | 1999 |